Ipratropium / Salbutamol Respules bulk supplier for pharma manufacturers

Ipratropium / Salbutamol Respules Suppliers & Bulk Manufacturers

Available Forms: Nebulizer Solution

Available Strengths: Ipratropium Bromide 0.5 mg + Albuterol Sulfate (equivalent to 3 mg salbutamol) 2.5 mg

Reference Brands: EU : Combivent® Nebules, Ipramol Steri-Neb®, Duovent® Nebuliser Solution; US: DuoNeb®

Ipratropium + Salbutamol Respules (DuoNeb®, Combivent®) are nebulized bronchodilators used for COPD and asthma. Each 2.5–3 mL dose contains Ipratropium 0.5 mg + Salbutamol 2.5 mg. Widely available in the US and EU, they offer quick, effective relief and are ideal for B2B, PCD, and global exports.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ipratropium Bromide + Salbutamol Respules are a trusted bronchodilator combination used for the treatment of COPD and acute asthma attacks. Available in the US as DuoNeb® and across the EU as Combivent®, Ipramol®, Duovent®, and generics, these respules deliver Ipratropium 0.5 mg + Salbutamol 2.5 mg via nebulization. This combo provides rapid, synergistic bronchodilation—ideal for patients requiring more than one bronchodilator. Packaged in convenient unit-dose vials (2.5–3 mL), they are suitable for pediatric and adult use. Perfect for pharma B2B, PCD, and global distribution, these Respules meet high demand in respiratory care markets worldwide.

Ipratropium / Salbutamol Respules — third party manufacturing & bulk supply

Ipratropium / Salbutamol Respules is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ipratropium / Salbutamol Respules is supplied as Nebulizer Solution — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ipratropium / Salbutamol Respules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ipratropium / Salbutamol Respules →

Back to Listing

Frequently Asked Questions

Ipratropium / Salbutamol Respules are used for the treatment and prevention of bronchospasm in patients with chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions. This combination helps provide quick and effective relief from breathing difficulties.

These respules are made from ipratropium bromide and salbutamol sulfate. Ipratropium is an anticholinergic bronchodilator that relaxes airway muscles, while salbutamol is a short-acting beta-2 agonist that quickly opens the airways.

Common trade names include Combivent (USA), DuoNeb (USA), Duolin Respules (India), Combimist Nebules, and various generic brands available in global markets.

The original combination products are marketed by Boehringer Ingelheim and GlaxoSmithKline. It is also manufactured by multiple companies worldwide including Cipla, Lupin, Sun Pharma, and other generic manufacturers.

The complete generic name is ipratropium bromide and salbutamol sulfate inhalation solution.

Brand names include Combivent, DuoNeb, Duolin Respules, Combimist Nebules, and various region-specific generic brands.

These respules are manufactured globally in countries such as the USA, UK, EU nations, India, and LATAM regions by both innovator and generic pharmaceutical companies.